Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc. is advancing its EB104 dual CD19/CD22 program, which demonstrates the potential for strategic partnerships to enhance its market position in addressing B-cell malignancies and autoimmune diseases. The company recently moved into a higher dose cohort following promising results from initial trials of EB103, indicating a favorable safety profile and the achievement of a complete response in at least one patient. Furthermore, the Estrella Artemis Technology platform offers a novel approach to CAR-T therapies, unlocking opportunities in immunology and solid tumor treatment, which could significantly broaden the company’s market potential going forward.

Bears say

Estrella Immunopharma Inc. is facing a challenging outlook primarily due to its reliance on the development of CD19 and CD22-targeted therapies, a high-risk area within the competitive oncology space. The financial data suggests a significant number of patients with relapsed/refractory B-cell Non-Hodgkin’s Lymphomas in China, highlighting potential market opportunities; however, the sheer volume of unmet medical needs also indicates fierce competition and regulatory hurdles. Additionally, without robust financial performance metrics or a clear path to profitability, the company's long-term sustainability and ability to capture market share remain in question.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.